Related Experiment Video
Updated: Nov 16, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
The effect of coagulation factors in 2019 novel coronavirus patients: A systematic review and meta-analysis
Guiling Xiang1, Shengyu Hao, Cuiping Fu
1Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China.
Insights
Coagulation dysfunction is linked to severe COVID-19 and higher mortality. Monitoring coagulation markers like D-dimer is crucial for managing severe cases and preventing complications.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- The association between coagulation dysfunction and severe Coronavirus Disease 2019 (COVID-19) remains unclear.
- Existing studies present inconsistent findings regarding the role of coagulopathy in COVID-19 patients.
Purpose of the Study:
- To investigate the impact of coagulation dysfunction on COVID-19 severity.
- To explore the relationship between coagulopathy and mortality in COVID-19 patients.
Main Methods:
- A systematic literature search was conducted across PubMed, Cochrane, and Embase databases (December 2019 - April 2020).
- Meta-analysis of observational studies following MOOSE guidelines was performed.
- Data on coagulation parameters (Platelets, PT, APTT, fibrin, D-dimer), dysfunction prevalence, and mortality were extracted and analyzed using meta-regression.
Main Results:
- Sixteen studies with 2,139 COVID-19 patients were included.
- Severe COVID-19 cases showed significantly higher D-dimer, PT, and fibrin levels, and more frequent coagulation dysfunction.
- Coagulopathy was associated with a substantially higher mortality risk (RR 10.86) and increased prevalence of Acute Respiratory Distress Syndrome (ARDS).
Conclusions:
- Coagulation dysfunction is associated with increased COVID-19 severity and mortality.
- Elevated PT, fibrin, and D-dimer levels may indicate disease progression and are linked to non-survival.
- Effective monitoring of coagulation function is essential for managing severe COVID-19 and preventing related coagulopathy, despite evidence quality limitations.
Background:
The role of coagulation dysfunction in Severe Coronavirus Disease 2019 (COVID-19) is inconsistent. We aimed to explore the impact of coagulation dysfunction amongst patients with COVID-19.
Methods:
We searched PubMed, Cochrane and Embase databases from December 1, 2019 to April 27, 2020 following Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Data about coagulation (Platelets, PT, APTT, fibrin, fibrinogen degradation products, D-dimer), prevalence of coagulation dysfunction and mortality were extracted. Meta regression was used to explore the heterogeneity.
Results:
Sixteen observational studies were included, comprising 2, 139 patients with confirmed COVID-19. More severe COVID-19 cases tended to have higher mean D-dimer (SMD 0.78, 95% CI 0.53 to 1.03, P < .001). The similar pattern occurred with PT and fibrin, with a contrary trend for PLTs. Coagulation dysfunction was more frequent in severe cases compared to less severe (SMD 0.46, 95% CI 0.25 to 0.67, P < .001). Higher mortality was associated with COVID-19-related coagulopathy (RR 10.86, 2.86 to 41.24, P < .001). Prevalence of ARDS was increased in more severe patients than less severe cases (RR 16.52, 11.27 to 24.22, P < .001). PT, fibrin and D-dimer levels elevated significantly in non-survivors during hospitalization.
Conclusion:
Presence of coagulation dysfunction might be associated with COVID-19 severity, and coagulopathy might be associated with mortality. Coagulation markers including PT, fibrin and D-dimer may imply the progression of COVID-19. This illuminates the necessity of effectively monitoring coagulation function for preventing COVID-19-related coagulopathy, especially in severe patients. For the obvious heterogeneity, the quality of the evidence is compromised. Future rigorous randomized controlled trials that assess the correlation between coagulation and COVID-19 are needed.
Trial Registration:
PROSPERO (CRD42020183514).
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins

